Aspar Pharmaceuticals Ltd Recalls Ibuprofen and Ibucalm 200mg Tablets Due to Packaging Defect
Areazine synthesizes this MHRA medicine alert directly from MHRA's official public data feed. See our methodology for full source attribution and refresh cadence.
Aspar Pharmaceuticals Ltd is recalling specific batches of Ibuprofen and Ibucalm 200mg tablets due to foil perforations found in blister packaging.
What this MHRA medicine alert tells you, and what most readers miss
This notice was issued by MHRA on April 6, 2026 and geographically references United Kingdom. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Medicine Alerts - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are recall, product-safety, mhra, Pharmaceuticals.
What Happened
Aspar Pharmaceuticals Ltd has issued a Class 3 medicines recall for specific batches of Ibuprofen 200mg tablets and Ibucalm 200mg tablets. The recall was initiated as a precautionary measure following the discovery of foil perforations in some of the blister packs.
Which Products Are Affected
The recall involves products distributed under the following liveries:
- Brand/Livery Names: Aspar, Almus, and Numark
- Product Names: Ibuprofen 200mg Tablets and Ibucalm 200mg Tablets
- Recall Identifier: EL(26)A/07
Specific batches distributed under these brands are affected by the packaging defect.
What You Should Do
Consumers should check their medication to determine if it belongs to the Aspar, Almus, or Numark brands. While the recall is a precautionary measure, individuals should contact their healthcare provider or the point of purchase for further guidance on affected batches and potential returns. Detailed information regarding the specific batch numbers can be found through the official MHRA alert portal.
Why This Matters
Foil perforations in blister packaging can compromise the integrity of the medication, potentially exposing the tablets to air or moisture, which may affect the product's quality or stability.
Source
Information provided by the MHRA (Medicines and Healthcare products Regulatory Agency).
Original source: MHRA Official Notice ↗
Related Medicine Alerts
All Medicine Alerts →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this MHRA medicine alert: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (1,530 characters here).
Similar severity timing
Same severity (medium) notices issued closest in time to April 6, 2026.
Frequently Asked Questions
Common questions about this MHRA medicine alert.